Email updates

Keep up to date with the latest news and content from BMC Biology and BioMed Central.

Journal App

google play app store
Open Access Commentary

Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas

Dharminder Chauhan* and Kenneth C Anderson

Author affiliations

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA

For all author emails, please log on.

Citation and License

BMC Biology 2011, 9:72  doi:10.1186/1741-7007-9-72

Published: 28 October 2011

Abstract

Current interest in proteasome inhibitors for cancer therapy has stimulated considerable research efforts to identify the molecular pathway to their cytotoxicity with a view to identifying the mechanisms of sensitivity and resistance as well as informing the development of new drugs. Zhao and Vuori describe this month in BMC Biology experiments indicating a novel role of the adaptor protein p130Cas in sensitivity to apoptosis induced not only by proteasome inhibitors but also by the unrelated drug doxorubicin.

See research article: http:// http://www.biomedcentral.com/1741-7007/9/73 webcite